Aura Biosciences to Host Virtual Ocular Oncology Event on May 29, 2024

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, is set to host a virtual Key Opinion Leader (KOL) event on Wednesday, May 29, 2024, at 2:00 PM ET. The event will highlight advancements in ocular cancer treatments and discuss the unmet medical needs and treatment landscape for conditions such as primary uveal melanoma, metastases to the choroid, and cancers of the ocular surface.

The panel will feature notable experts in the field, including Dr. Carol Shields of Wills Eye Hospital, Dr. Hakan Demirci of the University of Michigan, and Dr. Mandeep Sagoo from Moorfields Eye Hospital. These specialists will provide their insights into current treatment methodologies and discuss the potential of Aura's ocular oncology pipeline, particularly focusing on its leading candidate, bel-sar. Bel-sar is currently undergoing global Phase 3 clinical trials (CoMpass trial) as a potential first-line vision-preserving therapy for adult patients with early-stage uveal melanoma.

Dr. Anthony Daniels, Aura’s Therapeutic Area Head for Ocular Oncology, will join the discussion, which will be moderated by Chris Howerton, PhD, from LifeSci Advisors. The event will conclude with a live Q&A session, offering attendees the opportunity to engage directly with the experts.

The live webcast of the event will be accessible on Aura’s website under the “Investors & Media” section. For those unable to attend live, a replay will be available for 90 days post-event.

About the Featured Experts

Dr. Carol Shields is a distinguished authority in ophthalmology, having completed her training at Wills Eye Hospital and further fellowships in ocular oncology, oculoplastic surgery, and ophthalmic pathology. She currently serves as Director of the Oncology Service at Wills Eye Hospital and is a Professor of Ophthalmology at Thomas Jefferson University. Dr. Shields has an extensive publication record, including 12 textbooks and over 2000 peer-reviewed articles. She has received numerous accolades and serves on the editorial boards of several prestigious journals.

Dr. Hakan Demirci is the Richard N. and Marilyn K. Witham Professor of Ophthalmology and Visual Sciences at the University of Michigan's Kellogg Eye Center, where he also directs the Ocular Oncology Service. His expertise lies in the early detection and treatment of eye cancers. Dr. Demirci’s educational background includes a medical degree from Hacettepe University in Turkey and fellowships at Wills Eye Hospital and the University of Michigan. His research focuses on targeted therapies and metastasis prevention in ocular cancers.

Dr. Mandeep Sagoo holds positions as Professor of Ophthalmology and Ocular Oncology at UCL Institute of Ophthalmology and consultant ophthalmic surgeon at Moorfields Eye Hospital. He has received numerous academic awards and specializes in adult and pediatric eye tumors. Dr. Sagoo’s training includes a fellowship as a Fulbright Scholar at Wills Eye Hospital and a medical retina fellowship at Moorfields. He has led significant advancements in the field, including the development of the first fully digitally made 3D printed ocular prosthetic.

About Aura Biosciences

Aura Biosciences is dedicated to developing precision therapies for solid tumors that aim to preserve organ function. The company's leading candidate, bel-sar, is in late-stage development for primary uveal melanoma and other ocular cancers, and is also being explored for bladder cancer. The ongoing global Phase 3 CoMpass trial is evaluating bel-sar's efficacy and safety as a vision-sparing therapy for early-stage uveal melanoma. Aura’s mission is to improve patient outcomes through innovative, organ-preserving treatments. The company is headquartered in Boston, MA.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!